– Submission of Investigational New Drug Application (IND) to US FDA expected in 2025 – NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech ...

IO Biotech IOBT randomized 225 patients in its global Phase 3 clinical trial for IO102-IO103, in combination with Merck & Co Inc MRK Keytruda (pembrolizumab) in patients with advanced melanoma ...

--IO Biotech, a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, today announced that an ...